Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/14740338.2021.1962846 http://scihub22266oqcxt.onion/10.1080/14740338.2021.1962846 34328807!ä!34328807 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Expert+Opin+Drug+Saf 2021 ; 20 (12): 1559-1564 Nephropedia Template TP {{tp|p=34328807|t=2021. Assessment of adverse events associated with remdesivir use for coronavirus disease 2019 using real-world data |pdf=|usr=}}{{34328807}} gab.com Text Assessment of adverse events associated with remdesivir use for coronavirus disease 2019 using real-world data JO: Expert Opin Drug Saf http://www.kidney.de/pget.php?&tw=1&pmid=34328807 #FOAvip Background: Remdesivir has been used for treating patients with moderate to severe coronavirus disease 2019 (COVID-19) although there is conflicting evidence regarding its usefulness. Data regarding its safety largely come from the clinical trials conducted to support its emergency use authorization (EUA). This study aimed to identify the adverse events of remdesivir with disproportionately high reporting using real-world data.Research design and methods: The adverse event reports submitted to the United States Food and Drug Administration Adverse Event Reporting System (FAERS) by health-care professionals for drugs that have received EUA or approved for the treatment of COVID-19 in the US were studied. Adisproportionality analysis was performed to determine adverse events more frequently reported with remdesivir compared with other COVID-19 drugs in the database.Results: Elevated liver enzymes, acute kidney injury, raised blood creatinine levels, bradycardia, cardiac arrest, and death had disproportionately higher reporting with remdesivir as asuspect drug compared with other drugs. There is no significant difference in the reporting of these events based on patient sex or age.Conclusions: Our study confirms the drug label information regarding liver enzyme elevation. The renal and cardiac safety signals identified necessitate reevaluation for potential drug-labeling changes. Twit Text FOAVip Assessment of adverse events associated with remdesivir use for coronavirus disease 2019 using real-world data ????Expert Opin Drug Saf http://www.kidney.de/pget.php?&tw=1&pmid=34328807 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34328807 #FOAvip English Wikipedia <ref>{{Cite pmid|34328807}}</ref> Assessment of adverse events associated with remdesivir use for coronavirus disease 2019 using real-world data #MMPMID34328807 Singh A; Kamath A Expert Opin Drug Saf 2021[Dec]; 20 (12): 1559-1564 PMID34328807show ga Background: Remdesivir has been used for treating patients with moderate to severe coronavirus disease 2019 (COVID-19) although there is conflicting evidence regarding its usefulness. Data regarding its safety largely come from the clinical trials conducted to support its emergency use authorization (EUA). This study aimed to identify the adverse events of remdesivir with disproportionately high reporting using real-world data.Research design and methods: The adverse event reports submitted to the United States Food and Drug Administration Adverse Event Reporting System (FAERS) by health-care professionals for drugs that have received EUA or approved for the treatment of COVID-19 in the US were studied. Adisproportionality analysis was performed to determine adverse events more frequently reported with remdesivir compared with other COVID-19 drugs in the database.Results: Elevated liver enzymes, acute kidney injury, raised blood creatinine levels, bradycardia, cardiac arrest, and death had disproportionately higher reporting with remdesivir as asuspect drug compared with other drugs. There is no significant difference in the reporting of these events based on patient sex or age.Conclusions: Our study confirms the drug label information regarding liver enzyme elevation. The renal and cardiac safety signals identified necessitate reevaluation for potential drug-labeling changes. |*Acute Kidney Injury/chemically induced/diagnosis[MESH] |*Bradycardia/chemically induced/diagnosis[MESH] |*COVID-19 Drug Treatment[MESH] |*COVID-19/complications/epidemiology[MESH] |*Drug-Related Side Effects and Adverse Reactions/diagnosis/epidemiology/etiology[MESH] |*Liver Function Tests/methods/statistics & numerical data[MESH] |Adenosine Monophosphate/administration & dosage/adverse effects/*analogs & derivatives[MESH] |Adverse Drug Reaction Reporting Systems/statistics & numerical data[MESH] |Alanine/administration & dosage/adverse effects/*analogs & derivatives[MESH] |Antiviral Agents/administration & dosage/adverse effects[MESH] |Drug Approval/methods[MESH] |Female[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |SARS-CoV-2[MESH] |United States Food and Drug Administration/statistics & numerical data[MESH]Assessment of adverse events associated with remdesivir use for corona(epmc).pdf DeepDyve Pubget Overpricing